References
- Bramwell VH. Osteosarcomas and other cancers of bone. Curr Opin Oncol. 2000;12:330-6. https://doi.org/10.1097/00001622-200007000-00009
- Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003;9:1-9.
- Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998;284:751-9.
- Kim KY, Kim SS, Cheon HG. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol. 2006;72:530-40. https://doi.org/10.1016/j.bcp.2006.05.009
- Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003;22:5501-10. https://doi.org/10.1093/emboj/cdg513
- Kim JY, Kim TK, Park JY, Kim HJ, Lee JW. Effects of the peroxisome proliferator-activated receptor ligand troglitazone in osteosarcoma cell lines. J Korean Orthop Assoc. 2005;40:591-7. https://doi.org/10.4055/jkoa.2005.40.5.591
- Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997;44:1299-305. https://doi.org/10.1016/S0039-9140(97)00017-9
- Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/ MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999;91:1922-32. https://doi.org/10.1093/jnci/91.22.1922
- Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol. 2000;157:1123-8. https://doi.org/10.1016/S0002-9440(10)64627-5
- Moon SH, Lee SH, Kim HS, Kim CH, Chung TW. Phosphatase and Tensin Homologue Deleted on Chromosome 10) in Osteosarcoma. J Korean Orthop Assoc. 2003;38: 39-46. https://doi.org/10.4055/jkoa.2003.38.1.39
- Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1 dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem. 1998;273:13375-8. https://doi.org/10.1074/jbc.273.22.13375
- Stoll V, Calleja V, Vassaux G, Downward J, Lemoine NR. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut. 2005;54:109-16. https://doi.org/10.1136/gut.2004.046706
- Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005;114:242-8. https://doi.org/10.1002/ijc.20711
- Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004;64:5232-6. https://doi.org/10.1158/0008-5472.CAN-04-0272
- Cao LQ, Chen XL, Wang Q, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007;28:879-87. https://doi.org/10.1111/j.1745-7254.2007.00571.x
- Yim HW, Jong HS, Kim TY, et al. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res. 2005;65:1952-60. https://doi.org/10.1158/0008-5472.CAN-04-1740
- Okano H, Shiraki K, Inoue H, et al. 15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptorgamma- independent mechanism in hepatocellular carcinoma. Lab Invest. 2003;83:1529-39. https://doi.org/10.1097/01.LAB.0000092233.50246.F7
- Lemberger T, Desvergne B, Wahli W. Peroxisome proliferatoractivated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12:335-63. https://doi.org/10.1146/annurev.cellbio.12.1.335
- Jow L, Mukherjee R. The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPAR alpha and thyroid hormone receptors. J Biol Chem. 1995;270:3836-40. https://doi.org/10.1074/jbc.270.8.3836
- Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med. 2001;7:259-64. https://doi.org/10.1016/S1471-4914(01)02016-0
- Haydon RC, Zhou L, Feng T, Breyer B, et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 2002;8:1288-94.
- Haydon RC, Luu HH, He TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 2007;454:237-46. https://doi.org/10.1097/BLO.0b013e31802b683c